DrugPatentWatch Database Preview
Novartis Pharms Corp Company Profile
What is the competitive landscape for NOVARTIS PHARMS CORP, and what generic alternatives to NOVARTIS PHARMS CORP drugs are available?
NOVARTIS PHARMS CORP has fifty-nine approved drugs.
There are one hundred and twelve US patents protecting NOVARTIS PHARMS CORP drugs.
Summary for Novartis Pharms Corp
| US Patents: | 112 |
| Tradenames: | 51 |
| Ingredients: | 42 |
| NDAs: | 59 |
Drugs and US Patents for Novartis Pharms Corp
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis Pharms Corp | ZYKADIA | ceritinib | CAPSULE;ORAL | 205755-001 | Apr 29, 2014 | RX | Yes | Yes | 9,416,112 | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Novartis Pharms Corp | SIGNIFOR LAR KIT | pasireotide pamoate | FOR SUSPENSION;INTRAMUSCULAR | 203255-002 | Dec 15, 2014 | RX | Yes | No | 7,473,761 | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Novartis Pharms Corp | PROMACTA | eltrombopag olamine | TABLET;ORAL | 022291-004 | Oct 20, 2011 | RX | Yes | No | 6,280,959*PED | ➤ Sign Up | Y | ➤ Sign Up | |||
| Novartis Pharms Corp | PROMACTA | eltrombopag olamine | TABLET;ORAL | 022291-003 | Sep 8, 2009 | RX | Yes | Yes | 8,062,665*PED | ➤ Sign Up | Y | ➤ Sign Up | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for Novartis Pharms Corp
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Novartis Pharms Corp | CIPRO HC | ciprofloxacin hydrochloride; hydrocortisone | SUSPENSION/DROPS;OTIC | 020805-001 | Feb 10, 1998 | 5,965,549 | ➤ Sign Up |
| Novartis Pharms Corp | PATADAY | olopatadine hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 021545-001 | Dec 22, 2004 | 5,641,805*PED | ➤ Sign Up |
| Novartis Pharms Corp | IOPIDINE | apraclonidine hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 019779-001 | Dec 31, 1987 | 4,517,199 | ➤ Sign Up |
| Novartis Pharms Corp | AZOPT | brinzolamide | SUSPENSION/DROPS;OPHTHALMIC | 020816-001 | Apr 1, 1998 | 5,378,703*PED | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for NOVARTIS PHARMS CORP drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Ophthalmic Solution | 10.5% | ➤ Subscribe | 2012-02-29 |
| ➤ Subscribe | Ophthalmic Solution | 0.10% | ➤ Subscribe | 2006-07-17 |
| ➤ Subscribe | Ophthalmic Solution | 0.00% | ➤ Subscribe | 2009-02-19 |
| ➤ Subscribe | Nasal Spray | 0.665 mg/ Spray | ➤ Subscribe | 2009-06-29 |
| ➤ Subscribe | Otic Suspension | 0.3%/0.1% | ➤ Subscribe | 2012-07-31 |
| ➤ Subscribe | Ophthalmic Emulsion | 0.05% | ➤ Subscribe | 2014-05-01 |
| ➤ Subscribe | Tablets | 180 mg | ➤ Subscribe | 2015-10-23 |
| ➤ Subscribe | Tablets | 12.5 mg and 25 mg | ➤ Subscribe | 2014-02-04 |
| ➤ Subscribe | Tablets | 250 mg | ➤ Subscribe | 2011-03-14 |
| ➤ Subscribe | Injection | 1 mg/mL, 50 mL vials | ➤ Subscribe | 2011-12-16 |
| ➤ Subscribe | Ophthalmic Solution | 0.003% | ➤ Subscribe | 2015-12-30 |
| ➤ Subscribe | Ophthalmic Solution | 0.20% | ➤ Subscribe | 2008-09-08 |
| ➤ Subscribe | Ophthalmic Solution | 0.7% | ➤ Subscribe | 2015-09-10 |
| ➤ Subscribe | Ophthalmic | 0.50% | ➤ Subscribe | 2005-12-22 |
| ➤ Subscribe | Ophthalmic Suspension | 0.3% | ➤ Subscribe | 2015-12-21 |
| ➤ Subscribe | Tablets | 90 mg and 360 mg | ➤ Subscribe | 2015-10-19 |
| ➤ Subscribe | Tablets | 50 mg and 75 mg | ➤ Subscribe | 2014-01-07 |
| ➤ Subscribe | Tablets | 180 mg | ➤ Subscribe | 2016-04-28 |
| ➤ Subscribe | Injection | 100 mg/mL, 2.5 mL vials | ➤ Subscribe | 2007-09-24 |
| ➤ Subscribe | Oral Solution | 4 mg/5 mL | ➤ Subscribe | 2004-12-20 |
Non-Orange Book US Patents for Novartis Pharms Corp
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 8,912,205 | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors | ➤ Sign Up |
| 8,993,636 | Compositions containing moxifloxacin for treating otic infections | ➤ Sign Up |
| 8,088,813 | 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-y- lidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) | ➤ Sign Up |
| 7,906,644 | 2,4-pyrimidinediamine compounds and their uses | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
International Patents for Novartis Pharms Corp Drugs
Supplementary Protection Certificates for Novartis Pharms Corp Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 2015 00047 | Denmark | ➤ Sign Up | PRODUCT NAME: CERITINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/15/999 (C(2015)3218) 20150506 |
| 70017 | Netherlands | ➤ Sign Up | PRODUCT NAME: TOPOTECAN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARD BAAR ZOUT, HYDRAAT OF SOLVAAT, IN HET BIJZONDER HET HYDROCHLORI DE; NAT. REGISTRATION NO/DATE: EU/1/96/027/001 - EU/1/96/027/002 19961112; FIRST REGISTRATION: CH IKS 53857 19961016 |
| C/GB12/030 | United Kingdom | ➤ Sign Up | PRODUCT NAME: CYCLO((4R)-4-(2-AMINOETHYLCARBAMOYLOXY)-L-PROLYL-L-PHENYLGLYCYL-D-TRYPTOPHYL-L-LYSYL-4-O-BENZYL-L-TYROSYL-L-PHENYLALANYL-)), PASIREOTIDE, OR SALTS THEREOF; REGISTERED: UK EU/1/12/753/001-012 20120424 |
| 2010007 | Lithuania | ➤ Sign Up | PRODUCT NAME: ELTROMBOPAGUM OLAMINUM; REGISTRATION NO/DATE: EU/1/10/612/001, 2010 03 11 EU/1/10/612/002, 2010 03 11 EU/1/10/612/003, 2010 03 11 EU/1/10/612/004, 2010 03 11 EU/1/10/612/005, 2010 03 11 EU/1/10/612/006 20100311 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
